$2.43
2.47%
Downside
Day's Volatility :4.63%
Upside
2.21%
71.19%
Downside
52 Weeks Volatility :79.41%
Upside
28.53%
Period | Esperion Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 27.89% | 6.5% | 0.0% |
6 Months | 14.08% | 7.1% | 0.0% |
1 Year | 71.13% | 9.8% | 0.0% |
3 Years | -84.23% | 14.2% | -20.2% |
Market Capitalization | 443.3M |
Book Value | - $1.57 |
Earnings Per Share (EPS) | -0.9 |
PEG Ratio | -4.78 |
Wall Street Target Price | 7.36 |
Profit Margin | -37.65% |
Operating Margin TTM | 52.47% |
Return On Assets TTM | -6.94% |
Return On Equity TTM | -260.79% |
Revenue TTM | 229.7M |
Revenue Per Share TTM | 1.83 |
Quarterly Revenue Growth YOY | 466.09999999999997% |
Gross Profit TTM | -70.4M |
EBITDA | -34.6M |
Diluted Eps TTM | -0.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.01 |
EPS Estimate Next Year | 0.02 |
EPS Estimate Current Quarter | 0.05 |
EPS Estimate Next Quarter | -0.21 |
What analysts predicted
Upside of 202.88%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 184.5M | - |
Net Income | -201.8M | ↑ 20.85% |
Net Profit Margin | -109.4% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 148.4M | ↓ 19.57% |
Net Income | -109.0M | ↓ 45.98% |
Net Profit Margin | -73.48% | ↑ 35.92% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 227.5M | ↑ 53.37% |
Net Income | -166.2M | ↑ 52.44% |
Net Profit Margin | -73.04% | ↑ 0.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 78.4M | ↓ 65.52% |
Net Income | -318.8M | ↑ 91.84% |
Net Profit Margin | -406.42% | ↓ 333.38% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 75.5M | ↓ 3.79% |
Net Income | -287.8M | ↓ 9.73% |
Net Profit Margin | -381.34% | ↑ 25.08% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 116.3M | ↑ 54.14% |
Net Income | -209.2M | ↓ 27.3% |
Net Profit Margin | -179.87% | ↑ 201.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 18.8M | ↓ 0.85% |
Net Income | -68.5M | ↓ 0.22% |
Net Profit Margin | -363.81% | ↓ 2.32% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.3M | ↑ 29.29% |
Net Income | -89.2M | ↑ 30.32% |
Net Profit Margin | -366.72% | ↓ 2.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 25.8M | ↑ 5.99% |
Net Income | -49.9M | ↓ 44.03% |
Net Profit Margin | -193.65% | ↑ 173.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.0M | ↑ 31.73% |
Net Income | -41.3M | ↓ 17.39% |
Net Profit Margin | -121.43% | ↑ 72.22% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 32.3M | ↓ 5.06% |
Net Income | -56.3M | ↑ 36.59% |
Net Profit Margin | -174.71% | ↓ 53.28% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 137.7M | ↑ 327.09% |
Net Income | 61.0M | ↓ 208.3% |
Net Profit Margin | 44.3% | ↑ 219.01% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 143.5M | ↓ 48.37% |
Total Liabilities | 64.3M | ↑ 94.1% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 214.4M | ↑ 49.49% |
Total Liabilities | 194.5M | ↑ 202.33% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 353.3M | ↑ 64.73% |
Total Liabilities | 449.4M | ↑ 131.05% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 381.6M | ↑ 8.02% |
Total Liabilities | 578.5M | ↑ 28.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 247.9M | ↓ 35.02% |
Total Liabilities | 571.7M | ↓ 1.18% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 205.8M | ↓ 17.0% |
Total Liabilities | 660.8M | ↑ 15.58% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 247.9M | ↓ 20.74% |
Total Liabilities | 571.7M | ↓ 5.8% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 251.8M | ↑ 1.56% |
Total Liabilities | 581.5M | ↑ 1.71% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 234.6M | ↓ 6.83% |
Total Liabilities | 606.6M | ↑ 4.32% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 221.3M | ↓ 5.68% |
Total Liabilities | 631.3M | ↑ 4.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 205.8M | ↓ 7.01% |
Total Liabilities | 660.8M | ↑ 4.67% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 373.1M | ↑ 81.28% |
Total Liabilities | 667.4M | ↑ 0.99% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -148.6M | ↑ 13.2% |
Investing Cash Flow | 140.4M | ↓ 491.74% |
Financing Cash Flow | 10.7M | ↓ 93.46% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.3M | ↓ 52.68% |
Investing Cash Flow | 64.2M | ↓ 54.27% |
Financing Cash Flow | 136.2M | ↑ 1173.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -85.2M | ↑ 21.09% |
Investing Cash Flow | 21.4M | ↓ 66.75% |
Financing Cash Flow | 201.7M | ↑ 48.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -263.8M | ↑ 209.72% |
Investing Cash Flow | -50.5M | ↓ 336.39% |
Financing Cash Flow | 268.2M | ↑ 32.96% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -174.8M | ↓ 33.73% |
Investing Cash Flow | 8.1M | ↓ 116.05% |
Financing Cash Flow | 32.6M | ↓ 87.84% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -42.5M | ↓ 0.84% |
Investing Cash Flow | -11.8M | ↓ 135.74% |
Financing Cash Flow | -30.4M | ↓ 165.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -54.4M | ↑ 27.98% |
Investing Cash Flow | 25.0M | ↓ 311.97% |
Financing Cash Flow | 49.5M | ↓ 263.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.8M | ↓ 54.47% |
Investing Cash Flow | 17.5M | ↓ 30.0% |
Financing Cash Flow | 809.0K | ↓ 98.37% |
Sell
Neutral
Buy
Esperion Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Esperion Therapeutics, Inc. | 11.47% | 14.08% | 71.13% | -84.23% | -94.18% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Esperion Therapeutics, Inc. | NA | NA | -4.78 | 0.01 | -2.61 | -0.07 | NA | -1.57 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Esperion Therapeutics, Inc. | Buy | $443.3M | -94.18% | NA | -37.65% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Esperion Therapeutics, Inc.
Revenue is up for the last 2 quarters, 32.25M → 137.73M (in $), with an average increase of 76.6% per quarter
Netprofit is up for the last 2 quarters, -56.34M → 61.02M (in $), with an average increase of 192.3% per quarter
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 136.8%
Orbimed Advisors, LLC
Bellevue Group AG
Wasatch Advisors LP
Vanguard Group Inc
Great Point Partners LLC
Woodline Partners LP
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Organization | Esperion Therapeutics, Inc. |
Employees | 240 |
CEO | Mr. Sheldon L. Koenig |
Industry | Health Technology |
A Spac I Acquisition Corp
$2.43
+0.0%
Keyarch Acquisition Corp
$2.43
+0.0%
Connexa Sports Technologies Inc
$2.43
+0.0%
Us Value Etf
$2.43
+0.0%
First Wave Biopharma Inc
$2.43
+0.0%
Global X Msci Next Emerging
$2.43
+0.0%
Fat Projects Acquisition Corp
$2.43
+0.0%
Capital Link Global Fintech
$2.43
+0.0%
Applied Uv Inc
$2.43
+0.0%